Skip to content

Opko Health OPK Amortization expense related to capitalized debt issuance costs

Amortization expense related to capitalized debt issuance costs at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.13B+10.0%
P/S1.9×+0.5×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0.0×
Current ratio3.6×+1.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.

The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's amortization expense related to capitalized debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's amortization expense related to capitalized debt issuance costs?
Opko Health (OPK) reported amortization expense related to capitalized debt issuance costs of $137K in Q1 2026.
How has Opko Health's amortization expense related to capitalized debt issuance costs changed year-over-year?
Opko Health's amortization expense related to capitalized debt issuance costs decreased by 68.1% year-over-year, from $430K to $137K.
What is the long-term trend for Opko Health's amortization expense related to capitalized debt issuance costs?
Over 4 years (2021 to 2025), Opko Health's amortization expense related to capitalized debt issuance costs has grown at a 60.7% compound annual growth rate (CAGR), from $785K to $5.23M.